Table 1.
Comparison of Clinical Recipient and Donor Characteristics at Time of Transplant Among Liver Transplant Recipients With Human Immunodeficiency Virus Monoinfection
| Characteristic | LT Recipients With HIV Monoinfection | |||
|---|---|---|---|---|
| Overall (N = 246) |
Pre-INSTI (n = 78) |
INSTI (n = 168) |
P Value | |
| Age at transplant, y, median (IQR) | 53 (45–58) | 48 (44–55) | 54 (47–60) | .002 |
| Age, y | ||||
| ȃ<40 | 32 (13.1) | 10 (12.8) | 22 (13.1 | .952 |
| ȃ40–49 | 64 (26.0) | 31 (39.7) | 33 (19.6) | .001 |
| ȃ50–65 | 129 (52.4) | 34 (43.6) | 95 (56.6) | .058 |
| ȃ>65 | 21 (8.5) | 3 (3.9) | 18 (10.7) | .073 |
| Gender | ||||
| ȃFemale | 53 (21.5) | 17 (21.8) | 36 (21.4) | .948 |
| ȃMale | 193 (78.5) | 61 (78.2) | 132 (78.6) | .948 |
| Race/ethnicity | ||||
| ȃWhite | 138 (56.1) | 48 (61.5) | 90 (53.6) | .241 |
| ȃBlack/African American | 54 (22.0) | 22 (28.2) | 32 (19.1) | .106 |
| ȃHispanic/Latino | 41 (16.7) | 5 (6.4) | 36 (21.4) | .003 |
| ȃAsian | 10 (4.1) | 3 (3.9) | 7 (4.2) | .906 |
| Etiology of liver disease | ||||
| ȃAlcohol-related liver disease | 29 (11.8) | 2 (2.6) | 27 (16.1) | .002 |
| ȃNonalcoholic steatohepatitis | 38 (15.5) | 1 (1.3) | 37 (22.0) | <.001 |
| ȃHepatocellular carcinoma | 46 (18.7) | 19 (24.4) | 27 (16.1) | .121 |
| Diabetes mellitus | 52 (21.1) | 11 (14.1) | 41 (24.4) | .066 |
| Obesity (BMI ≥30 kg/m2) | 62 (25.2) | 13 (16.7) | 49 (29.2) | .036 |
| Dialysis | 23 (9.4) | 5 (6.4) | 18 (10.7) | .281 |
| Hepatic decompensation at transplantation | ||||
| ȃSevere hepatic encephalopathy | 38 (15.5) | 17 (21.8) | 21 (12.5) | .061 |
| ȃModerate ascites | 66 (26.8) | 16 (20.5) | 50 (29.8) | .128 |
| ȃPortal venous thrombosis | 39 (15.9) | 7 (9.0) | 32 (19.1) | .044 |
| ȃHistory of SBP | 15 (6.1) | 1 (1.3) | 14 (8.3) | .031 |
| Donor CMV IgG+/recipient CMV IgG– | 6 (2.4) | 6 (7.7) | 0 | <.001 |
| Donor EBV IgG+/recipient EBV IgG– | 18 (7.3) | 7 (9.0) | 11 (6.6) | .496 |
| Wait time to LT, mo, median (IQR) | 2.2 (0.2–7.5) | 2.8 (0.2–13.2) | 1.9 (0.2–6.0) | .125 |
| Laboratory MELD score at LT, median (IQR) | 22.5 (13–32) | 19.5 (12–32) | 24 (14–32) | .299 |
| Recipient HBsAg positive | 68 (27.6) | 32 (41.0) | 36 (21.4) | .001 |
| Donor characteristics | ||||
| ȃAge, y, median (IQR) | 41 (26–54) | 45 (31–56) | 39 (25–53) | .080 |
| ȃBlack/African American | 46 (18.7) | 15 (19.2) | 31 (18.5) | .884 |
| ȃMale | 143 (58.1) | 34 (43.6) | 109 (64.9) | .002 |
| ȃCold ischemia time, h, median (IQR) | 5.9 (4.6–7.6) | 6.9 (5–8.2) | 5.5 (4.5–7) | <.001 |
| ȃWarm ischemia time, min, median (IQR) | 13 (10–19) | 11 (10–13) | 21 (19–23) | .053 |
| ȃHCV antibody positive | 4 (1.6) | 0 | 4 (2.4) | .169 |
| ȃHIV positive | 14 (5.7) | 0 | 14 (8.3) | .009 |
| ȃHistory of drug use | 105 (42.7) | 22 (28.2) | 83 (49.4) | .002 |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: BMI, body mass index; CMV, cytomegalovirus; EBV, Epstein-Barr virus; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IgG, immunoglobulin G; INSTI, integrase strand transfer inhibitor; IQR, interquartile range; LT, liver transplant; MELD, Model for End-Stage Liver Disease; SBP, spontaneous bacterial peritonitis.